<DOC>
	<DOCNO>NCT00013702</DOCNO>
	<brief_summary>This study evaluate safety effectiveness add experimental drug adefovir dipivoxil lamivudine treat hepatitis B virus ( HBV ) infection HIV-infected patient liver cirrhosis . Adefovir inhibit HBV interfere replication virus 's genetic material . In people , drug active strain HBV resistant lamivudine ; may also activity HIV . HIV-infected patient 21 year age old chronic hepatitis B infection liver cirrhosis receive lamivudine treatment least 1 year may eligible 48-week study . Candidates screen complete medical history , blood test 24-hour urine collection . Blood test include HLA typing ( test genetic marker white blood cell permit specialized immunology study ) . Within 4 week , candidate appear eligible study physical examination medical history , abdominal ultrasound ( image test use sound wave ) check cancer liver , chest X-ray electrocardiogram ( EKG ) . Blood urine test also do , woman become pregnant pregnancy test . Patients meet study criterion decide participate start treatment one 10-mg adefovir pill per day mouth . In addition , patient continue take medication prescribe doctor . Follow-up clinic visit schedule follow : - Days 1 , 3 , 5 , 7 , 10 21 - Blood drawn specialize immunology test measure blood level HIV HBV . - Weeks 2 , 4 , 8 , 12 , 16 , 20 , 24 , 28 , 32 , 36 , 40 , 44 - Blood urine ( single sample ) test do determine side effect adefovir effect HBV infection . - Week 48 early termination ( end study ) - Blood test ( include test hepatitis C D ) , abdominal ultrasound 24-hour urine collection evaluate kidney function do . - Monthly visit beyond week 48 - Based HBV response treatment availability drug sponsor , patient may offer extend treatment adefovir . Those continue monthly follow-up visit blood urine ( single sample ) test .</brief_summary>
	<brief_title>Adefovir Dipivoxil Treat Hepatitis B HIV-Infected Patients</brief_title>
	<detailed_description>Patients co-infected human immunodeficiency virus ( HIV ) hepatitis B virus ( HBV ) advance liver disease ( decompensated cirrhosis Child-Pugh score know cause hepatitis HBV ) , HBV viral load least 1 million copies/mL blood , least one year therapy lamivudine treat open-label adefovir dipivoxil 10 mg daily lamivudine 150 mg bid evaluate safety efficacy regimen patient group obtain specimens study immune response HBV HIV-infected patient . Additionally kinetics viral load response adefovir assess . Specimens store possible use evaluate HBV HIV resistance adefovir . L-carnitine supplementation use low serum carnitine level document . Patients follow HBV viral load response adefovir 48 week possible extension . The primary study endpoint HBV viral load week 24 ( per-protocol patient ) DAVG week 24 ( intent-to-treat patient ) . Adefovir discontinue toxicity ; dose reduction . Up 30 subject enrol .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Adefovir</mesh_term>
	<mesh_term>Adefovir dipivoxil</mesh_term>
	<criteria>INCLUSION CRITERIA : Age great equal 18 year Infection HBV HBV viral load great equal 1.0 x 10 ( 6 ) copies/mL Roche assay screen HIVinfected document ELISA Western Blot NIAID clinic ( CD4/HIV viral load ) Decompensated cirrhosis ( ChildPugh Score great equal 7 : Class B C cirrhosis ) Class A Score 6 acceptable secondary ascites grade encephalopathy laboratory abnormality ( PT , albumin , bilirubin ) . Able return NIH study visit Have physician ( ) outside NIH provide routine , well HIV liver specific , care . Receiving lamivudine dose least 100 mg qd great equal one year prior enrollment ( dose interruption great 1 month total previous year interruption 3 month prior study entry ) Serum creatinine le 1.5 mg/dL Serum phosphorus great equal 2.2 mg/dL ( normal range NIH 2.34.3 mg/dL ) Neutrophil count great equal 1000 cells/mm ( 3 ) Platelets great equal 50,000/mm ( 3 ) Hemoglobin great equal 8.0 mg/dL ALT le equal 287 ( 7 X NIH upper limit normal ) Not pregnant breastfeeding . Pregnancy test must negative within two week prior dose study medication . If capable pregnancy : use effective contraception study : effective contraception method include abstinence , surgical sterilization either partner , barrier method diaphragm , condom , cap sponge , use hormonal contraception antiHIV regimen alter metabolism hormonal contraception Willing able provide write informed consent Because liver disease result encephalopathy , willing designate person durable power attorney NIH form medical research medical care purpose NIH Clinical Center EXCLUSION CRITERIA : Prior use ADV ( outside patient receive adefovir NIH emergency use IND ) prior use tenofovir , cidofovir Active serious systemic infection HIV HBV Liver disease cause reason hepatitis B e.g. , HCV , HDV , Wilson 's , hemochromatosis , autoimmune hepatitis ( ANA great equal 160 ) except history drugassociated hepatitis discontinuation causative agent History significant encephalopathy History clinically significant pancreatitis History untreated varix New AIDSdefining event esophageal candidiasis diagnose within one month prior baseline Decompensated heart failure Treatment immunomodulator drug ( interferon , interleukin , corticosteroid great physiologic dos ) 4 week prior baseline . GCSF epoietin use permit . AntiHBV therapy lamivudine ( emtricitabine , lobucavir , entecavir , HBIG , clevudine , MCC478 ) exception interferon alpha , famciclovir foscarnet end 12 week prior screen . Hepatic mass suggestive hepatocellular carcinoma Alphafetoprotein level great equal 200ng/mL Evidence gastrointestinal malabsorption chronic nausea vomit Current alcohol substance abuse potentially could interfere patient compliance Malignancy cutaneous Kaposi 's sarcoma , skin cancer treat resection HPVassociated carcinoma situ Bowen 's disease 5 year prior enrollment History clinically significant renal dysfunction within previous 12 month prior baseline Concomitant therapy aminoglycosides , amphotericin B , cidofivir , cisplatinum , IV pentamidine , vancomycin , systemic chemotherapeutic agent , probenecid nephrotoxic agent Proteinuria ( great equal 3+ ) ANA great equal 3 EU Positive PCR test hepatitis C Antibodies hepatitis D ( delta hepatitis ) Pregnancy breastfeed History organ bone marrow transplantation Any systemic illness make unlikely subject able return NIH require study visit .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2004</verification_date>
	<keyword>Immunology</keyword>
	<keyword>Cirrhosis</keyword>
	<keyword>Ascites</keyword>
	<keyword>Open-Label</keyword>
	<keyword>Chronic</keyword>
	<keyword>HIV</keyword>
	<keyword>Hepatitis B</keyword>
</DOC>